Rebecca Garris

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

Deborah A. Thomas, Susan O’Brien, Stefan Faderl et al. · Journal of Clinical Oncology · 2010 · 412 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Naval Daver, Deborah A. Thomas, Farhad Ravandi et al. · Haematologica · 2015 · 227 citations · Full text

Medicine, Hematology, Oncology +14

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Elias Jabbour, Farhad Ravandi et al. · Cancer · 2016 · 203 citations · Full text

Medicine, Oncology, Pharmacology +12

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Farhad Ravandi, Jeffrey L. Jorgensen, Susan O’Brien et al. · British Journal of Haematology · 2015 · 116 citations · Full text

Medicine, Hematology, Oncology +17

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>‐cell acute lymphoblastic leukemia

Elias Jabbour, Nicholas J. Short, Jeffrey L. Jorgensen et al. · Cancer · 2016 · 75 citations · Full text

Medicine, Oncology, Chemotherapy +16